Systematic assessment of fluid responsiveness during early septic shock resuscitation: Secondary analysis of the ANDROMEDA-SHOCK trial

Eduardo Kattan, Gustavo A. Ospina-Tascón, Jean Louis Teboul, Ricardo Castro, Maurizio Cecconi, Giorgio Ferri, Jan Bakker, Glenn Hernández, Glenn Hernandez, Lucas Petri Damiani, Elisa Estenssoro, Arnaldo Dubin, Javier Hurtado, Gilberto Friedman, Ricardo Castro, Leyla Alegría, Jean Louis Teboul, Giorgio Ferri, Manuel Jibaja, Ronald PairumaniPaula Fernández, Diego Barahona, Alexandre Biasi Cavalcanti, Jan Bakker, Glenn Hernandez, Leyla Alegría, Giorgio Ferri, Nicolás Rodriguez, Patricia Holger, Natalia Soto, Mario Pozo, Jan Bakker, Deborah Cook, Jean Louis Vincent, Bryan P. Kavanagh, Phil Dellinger, Wim Rietdijk

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Background: Fluid boluses are administered to septic shock patients with the purpose of increasing cardiac output as a means to restore tissue perfusion. Unfortunately, fluid therapy has a narrow therapeutic index, and therefore, several approaches to increase safety have been proposed. Fluid responsiveness (FR) assessment might predict which patients will effectively increase cardiac output after a fluid bolus (FR+), thus preventing potentially harmful fluid administration in non-fluid responsive (FR-) patients. However, there are scarce data on the impact of assessing FR on major outcomes. The recent ANDROMEDA-SHOCK trial included systematic per-protocol assessment of FR. We performed a post hoc analysis of the study dataset with the aim of exploring the relationship between FR status at baseline, attainment of specific targets, and clinically relevant outcomes. Methods: ANDROMEDA-SHOCK compared the effect of peripheral perfusion- vs. lactate-targeted resuscitation on 28-day mortality. FR was assessed before each fluid bolus and periodically thereafter. FR+ and FR- subgroups, independent of the original randomization, were compared for fluid administration, achievement of resuscitation targets, vasoactive agents use, and major outcomes such as organ dysfunction and support, length of stay, and 28-day mortality. Results: FR could be determined in 348 patients at baseline. Two hundred and forty-two patients (70%) were categorized as fluid responders. Both groups achieved comparable successful resuscitation targets, although non-fluid responders received less resuscitation fluids (0 [0-500] vs. 1500 [1000-2500] mL; p 0.0001), exhibited less positive fluid balances, but received more vasopressor testing. No difference in clinically relevant outcomes between FR+ and FR- patients was found, including 24-h SOFA score (9 [5-12] vs. 8 [5-11], p = 0.4), need for MV (78% vs. 72%, p = 0.16), need for RRT (18% vs. 21%, p = 0.7), ICU-LOS (6 [3-11] vs. 6 [3-16] days, p = 0.2), and 28-day mortality (40% vs. 36%, p = 0.5). Only thirteen patients remained fluid responsive along the intervention period. Conclusions: Systematic assessment allowed determination of fluid responsiveness status in more than 80% of patients with early septic shock. Fluid boluses could be stopped in non-fluid responsive patients without any negative impact on clinical relevant outcomes. Our results suggest that fluid resuscitation might be safely guided by FR assessment in septic shock patients. Trial registration: ClinicalTrials.gov identifier, NCT03078712. Registered retrospectively on March 13, 2017.

Original languageEnglish
Article number23
JournalCritical Care
Volume24
Issue number1
DOIs
StatePublished - 23 Jan 2020

Keywords

  • Early resuscitation
  • Fluid overload
  • Fluid responsiveness
  • Septic shock

Fingerprint

Dive into the research topics of 'Systematic assessment of fluid responsiveness during early septic shock resuscitation: Secondary analysis of the ANDROMEDA-SHOCK trial'. Together they form a unique fingerprint.

Cite this